January 9, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology…
Pharmaceuticals, Biotechnology and Life Sciences
WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology…
International Medical Cannabis Revenue Increases 36%; Canadian Adult-Use Cannabis Revenue Grows 6% Tilray Pharma Achieves Record Quarterly Revenue U.S. Federal…
Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase…
PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company…
Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium PresentationHOUSTON, Jan. 08, 2026…
SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology…
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in…
— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years– BRISBANE,…
– Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks…
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the…